Guohua Pan

This inventor holds 18 USPTO granted patents and 5 published patent applications, plus 21 CIPO patents and 5 EPO patents, primarily in Cancer Therapeutics. Top assignees: University Health Network, University of Toronto, Antlera Therapeutics Inc.. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Guohua Pan. Retrieved from https://idiyas.com/inventor/guohua-pan-703bgph9

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 5)

% Patents Active = 77.8

CIPO Patents = 21 (Patent Applications = 6)

EPO Patents = 5 (Patent Applications = 12)

Average Co-Inventor Count = 4.0

ph-index = 6

Forward Citations = 91(Granted Patents)

Company Filing History:

10 out of 312

University Health Network

patents

4 out of 532

University of Toronto

patents

2 out of 2

Antlera Therapeutics Inc.

Modmab Therapeutics Corporation

patent

6. 1 out of 88

Shanghaitech University

patents

7. 1 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

Pancreatic Cancer

Kinase Inhibitors

Antibodies

Frizzled Receptors

PTEN Mutant Diseases

Carnitine Palmitoyltransferase

CD133-Binding Agents

Human Interleukin

Neuropeptide Y

TTK Antagonists

Tumor Growth Inhibition

Indolinone Derivatives

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12600785 - Method of screening for compounds that inhibit proliferation of pancreatic cancer cells having a loss-of-function mutation in the RNF43 gene (2026-04-14),

2. 12595312 - CD133-BINDING AGENTS AND USES THEREOF (2026-04-07),

3. 12583919 - ANTIBODIES THAT BIND TO LRP6 PROTEINS AND METHODS OF USE (2026-03-24),

4. 12240909 - Human antibodies to human interleukin 18 receptor alpha or beta (2025-03-04),

5. 11220551 - CD133-binding agents and uses thereof (2022-01-11),

6. 10919968 - Frizzled5 protein-binding agents (2021-02-16),

7. 10689442 - Antibodies against Frizzled receptor (2020-06-23),

8. 10077304 - Antibodies against frizzled receptor (2018-09-18),

9. 9402828 - Methods of targeting PTEN mutant diseases and compositions therefor (2016-08-02),

10. 8999968 - Kinase inhibitors and method of treating cancer with same (2015-04-07),

11. 8933070 - Methods of targeting PTEN mutant diseases and compositions therefor (2015-01-13),

12. 8765791 - Method of treating cancer using a neuropeptide Y 5R (NP Y5R) antagonist (2014-07-01),

13. 8765748 - Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer (2014-07-01),

14. 8680282 - Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer (2014-03-25),

15. 8492356 - Methods of inhibiting tumor growth using TTK antagonists (2013-07-23),

Title: The Innovative Contributions of Guohua Pan

Introduction

Guohua Pan is a prominent inventor based in Oakville, Canada, known for his significant contributions to the field of biotechnology. With a total of 15 patents to his name, he has made remarkable advancements in the development of therapeutic agents and diagnostic tools.

Latest Patents

Among his latest patents, Guohua Pan has developed human antibodies to human interleukin 18 receptor alpha or beta. These antibodies or fragments exhibit binding specificity to the anti-IL-18 receptor alpha or beta. The methods associated with these antibodies are aimed at treating and diagnosing diseases such as cancer, as well as inflammatory and autoimmune diseases. Another notable patent involves CD133-binding agents, which are directed towards novel agents that can detect CD133-expressing cells. This patent also outlines the uses of these agents for quantifying levels of cellular CD133 expression, targeting CD133-expressing cells, and treating or preventing cancer.

Career Highlights

Guohua Pan has had a distinguished career, working with esteemed institutions such as the University Health Network and the University of Toronto. His work has significantly impacted the field of medical research and therapeutic development.

Collaborations

Throughout his career, Guohua Pan has collaborated with notable professionals, including Miklos Feher and Peter Brent Sampson. These collaborations have further enhanced his research and innovation efforts.

Conclusion

Guohua Pan's innovative work in biotechnology, particularly in the development of therapeutic antibodies and CD133-binding agents, showcases his dedication to advancing medical science. His contributions continue to influence the fields of cancer treatment and diagnostics.

Profile summary based on public USPTO records.